1. Scrip
  2. >>Business

CEO Hudson: No Rust On Sanofi Launch Engine

 
• By Kevin Grogan

Some analysts have expressed concern in the past about the French drugmaker’s product launchpad but CEO Paul Hudson has dismissed such claims, pointing to the spectacular lift off of Beyfortus.

Sanofi
• Source: Sanofi

Having spent the past three months touting Sanofi's credentials as the pharma industry's leader in immunology R&D, CEO Paul Hudson has turned the spotlight on the French major's ability to launch products successfully, a position backed up by the stellar performance of the AstraZeneca PLC-partnered infant respiratory syncytial virus vaccine Beyfortus.

Presenting Sanofi's financials at its annual press conference in Paris, Hudson noted that the firm's key launches in 2023 – Beyfortus (nirsevimab), Altuviiio (efanesoctocog alfa) for hemophilia A and the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Novo Nordisk’s CEO forced out; quantifying biopharma’s contribution to the US economy; a history of MASH deals; lift for AstraZeneca’s asthma ambitions; and major Japanese firms see US revenue growth.

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

Progress In The Effort To Improve Outcomes In SCLC

 
• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.